Patients with myelodysplastic syndromes (MDS) frequently become dependent on blood transfusions.
We analyzed the total transfusion support required, and its complications and cost, following the diagnosis of MDS (total period=79.7 patient-years) in 50 patients followed at the Minneapolis VA Medical Center.
From diagnosis of MDS to transformation to AML or death (the MDS phase), 41 patients (82%) required transfusions.
The median numbers of transfused blood products per patient per year of follow-up in the MDS phase were : packed red blood cells (pRBC), 11.1 (range, 0-91.3) units, random donor platelets (RDP), 6.8 (range, 0-581) units, and single donor apheresis platelet packs (SDP) : 0 (range, 0-40) collections.
In the AML phase (time from diagnosis of secondary AML to death or last follow-up), median transfusion requirements per patient (n=5) were 24 (range, 8-88) units pRBC, 94 (range, 24-480) units RDP and 3 (range, 0-19) collections of SDP.
Overall, 80% of patients required either special processing or selection of blood products, had reactions to blood products or required premedications (specified/complicated transfusions) ; 94% of all pRBC and 97% of all platelet transfusions were specified/complicated.
The median cost of transfusions per patient was $4048 (range, $0-73 210) during the MDS phase and $13 210 (range, $5288-59 010) during the AML phase. (...)
Mots-clés Pascal : Myélodysplasique syndrome, Transfusion, Constituant sang, Long terme, Traitement, Analyse coût, Economie santé, Complication, Homme, Erythrocyte, Thrombocyte, Hémopathie maligne
Mots-clés Pascal anglais : Myelodysplastic syndrome, Transfusion, Blood product, Long term, Treatment, Cost analysis, Health economy, Complication, Human, Red blood cell, Platelet, Malignant hemopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0514528
Code Inist : 002B27D01. Création : 18/05/2000.